Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in TNBC
NCT07342283Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in triple-negative breast cancer (TNBC), sponsored by Affiliated Hospital of Nantong University. Started Feb 2026; status: recruiting.
02
Drugs
QL1706
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07342283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342283.